Literature DB >> 22715217

Continuous renal replacement treatment and the 'bleeding patient'.

Hugh Davies1, Gavin Leslie, David Morgan.   

Abstract

A woman suspected of intra-abdominal bleeding with end-stage renal failure requiring maintenance haemodialysis was treated with continuous veno-venous haemodiafiltration in the intensive care unit. The use of citrate restricted to the extracorporeal circuit maintained continuity of treatment and avoided the adverse affects of systemic anticoagulation. Regional citrate anticoagulation was achieved using the 'modified' Alabama Protocol. A description of the protocol is included along with troubleshooting instructions. Violations of the protocol challenged the adequacy of workforce training and patient monitoring, which saw systemic ionised calcium level reach 0.62 mmol/litre and base deficit drop -14.7. After protocol transgressions were corrected the patient was successfully treated and satisfactory biochemical control achieved without placing the patient at increased risk of bleeding. Training and vigilance in the use of citrate is essential to maintain patient safety.

Entities:  

Mesh:

Year:  2011        PMID: 22715217      PMCID: PMC3027079          DOI: 10.1136/bcr.01.2009.1523

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations.

Authors:  Sandeep Munjal; A Ahsan Ejaz
Journal:  Nephrology (Carlton)       Date:  2006-10       Impact factor: 2.506

2.  Continuous veno-venous hemofiltration without anticoagulation in high-risk patients.

Authors:  H K Tan; I Baldwin; R Bellomo
Journal:  Intensive Care Med       Date:  2000-11       Impact factor: 17.440

3.  Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A.

Authors:  M J Flanigan; L Pillsbury; G Sadewasser; V S Lim
Journal:  Am J Kidney Dis       Date:  1996-04       Impact factor: 8.860

4.  Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions.

Authors:  Olivier Cointault; Nassim Kamar; Pierre Bories; Laurence Lavayssiere; Olivier Angles; Lionel Rostaing; Michèle Genestal; Dominique Durand
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

5.  A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration.

Authors:  Marc Dorval; François Madore; Sylvie Courteau; Martine Leblanc
Journal:  Intensive Care Med       Date:  2003-05-22       Impact factor: 17.440

6.  A regional citrate anticoagulation protocol for pre-dilutional CVVHDf: the 'Modified Alabama Protocol'.

Authors:  Hugh Davies; David Morgan; Gavin Leslie
Journal:  Aust Crit Care       Date:  2008-07-16       Impact factor: 2.737

7.  A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance.

Authors:  Ashita J Tolwani; Mary B Prendergast; Rajesh R Speer; Brenda S Stofan; Keith M Wille
Journal:  Clin J Am Soc Nephrol       Date:  2005-11-23       Impact factor: 8.237

8.  Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.

Authors:  Santo Morabito; Isabella Guzzo; Angela Solazzo; Lina Muzi; Remo Luciani; Alessandro Pierucci
Journal:  J Nephrol       Date:  2003 Jul-Aug       Impact factor: 3.902

9.  Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.

Authors:  R Swartz; D Pasko; J O'Toole; B Starmann
Journal:  Clin Nephrol       Date:  2004-02       Impact factor: 0.975

Review 10.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.